Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetic cardiomyopathy (DCM) is a distinct clinical entity of diabetic heart muscle that describes diabetes associated changes in the structure and function of the myocardium in the absence of coronary artery disease, hypertension, and valvular disease. Oxidative stress plays a critical role in DCM development. DCM can be diagnosed using the novel methods of echocardiography (tissue Doppler imaging, Speckling tracking techniques and more recent real time 4D echocardiography). There is a possible cardioprotective effect of statins, Captopril and L-Carnitine in type 1 diabetic children and adolescents.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| diabetic- no cardioprotectives | No Intervention | 25 child with type 1 diabetes mellitus will not receive any cardio protective drug | |
| diabetic-Atorvastatin | Experimental | 25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day) |
|
| diabetic-Captopril | Experimental | 25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day) |
|
| diabetic-L-Carnitine | Experimental | 25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day) |
|
| Controls | No Intervention | 50 healthy children, of matched age and sex, with no symptoms of cardiac diseases |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin | Drug | cardio-protective agents |
| |
| Captopril |
| Measure | Description | Time Frame |
|---|---|---|
| The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents. | Corrected QT interval(QTc) and QT dispersion in ElectroCardioGram | before and after 4 months of receiving cardio-protective agents |
| The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents. | Left Ventricular End Systolic Volume (ml). Left Ventricular End Diastolic Volume (ml). Ejection Fraction (EF %) and left ventricular strain using echocardiography. | before and after 4 months of receiving cardio-protective agents |
| Measure | Description | Time Frame |
|---|---|---|
| The role of Troponin I levels as a cardiac marker for detection of asymptomatic cardiovascular insult in diabetic children. | Serum Cardiac troponin I by Enzyme Linked ImmunoSorbant Assay | first day |
| The role of recent echocardiographic parameters for early detection of silent myocardial dysfunction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medicine- Tanta University | Tanta | Gharbia Governorate | 0000 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33536102 | Derived | Badreldeen A, El Razaky O, Erfan A, El-Bendary A, El Amrousy D. Comparative study of the efficacy of captopril, simvastatin, and L-carnitine as cardioprotective drugs in children with type 1 diabetes mellitus: a randomised controlled trial. Cardiol Young. 2021 Aug;31(8):1315-1322. doi: 10.1017/S1047951121000226. Epub 2021 Feb 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
cardio-protective agents |
|
| L-carnitine | Drug | cardio-protective agents |
|
Echocardiography |
| first day |
| Identification of risk factors for developing diabetic cardiac insult. | first day |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D002216 | Captopril |
| D002331 | Carnitine |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D011392 | Proline |
| D007098 | Imino Acids |
| D000598 | Amino Acids, Cyclic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D050337 | Trimethyl Ammonium Compounds |
| D000644 | Quaternary Ammonium Compounds |
| D000588 | Amines |
| D009930 | Organic Chemicals |
Not provided
Not provided